Detalhe da pesquisa
1.
Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera.
N Engl J Med
; 390(8): 723-735, 2024 Feb 22.
Artigo
Inglês
| MEDLINE | ID: mdl-38381675
2.
Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL.
Blood
; 143(16): 1646-1655, 2024 Apr 18.
Artigo
Inglês
| MEDLINE | ID: mdl-38142448
3.
An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML.
Blood
; 141(3): 295-308, 2023 01 19.
Artigo
Inglês
| MEDLINE | ID: mdl-36260765
4.
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Lancet
; 401(10373): 269-280, 2023 01 28.
Artigo
Inglês
| MEDLINE | ID: mdl-36709073
5.
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes.
Oncologist
; 28(10): 901-910, 2023 10 03.
Artigo
Inglês
| MEDLINE | ID: mdl-37120291
6.
Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.
Blood
; 138(5): 387-400, 2021 08 05.
Artigo
Inglês
| MEDLINE | ID: mdl-34351368
7.
Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration.
Haematologica
; 108(12): 3321-3332, 2023 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37408464
8.
Treatment Patterns, Health Care Resource Utilization, and Cost in Patients with Myelofibrosis in the United States.
Oncologist
; 27(3): 228-235, 2022 03 11.
Artigo
Inglês
| MEDLINE | ID: mdl-35274711
9.
The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.
BMC Cancer
; 22(1): 1013, 2022 Sep 24.
Artigo
Inglês
| MEDLINE | ID: mdl-36153475
10.
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 20(9): 1033-1062, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-36075392
11.
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes.
Acta Haematol
; 145(4): 448-453, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-35008087
12.
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
Future Oncol
; 18(27): 2987-2997, 2022 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-35950489
13.
Toxicity analysis of busulfan pharmacokinetic therapeutic dose monitoring.
J Oncol Pharm Pract
; : 10781552221104422, 2022 Jun 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35673764
14.
Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Biol Blood Marrow Transplant
; 26(2): 262-271, 2020 02.
Artigo
Inglês
| MEDLINE | ID: mdl-31610237
15.
Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study.
Biol Blood Marrow Transplant
; 26(3): 472-479, 2020 03.
Artigo
Inglês
| MEDLINE | ID: mdl-31669399
16.
Correction to: The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion.
Ann Hematol
; 99(1): 21, 2020 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31788722
17.
The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion.
Ann Hematol
; 99(1): 7-19, 2020 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-31650290
18.
Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 18(9): 1248-1269, 2020 09.
Artigo
Inglês
| MEDLINE | ID: mdl-32886902
19.
Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib.
Haematologica
; 109(2): 676-681, 2024 Feb 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37259556
20.
Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant
; 24(5): 1029-1034, 2018 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29369800